戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nctional avidity toward the native epitope ("heteroclitic").
2 ld-type epitopes could be modified to obtain heteroclitic activity.
3  peripheral blood mononuclear cells with two heteroclitic analogs resulted in recruitment of more num
4                  The biological relevance of heteroclitic analogs was underlined when predicted analo
5 HLA)-A2.1-restricted epitopes and found that heteroclitic analogs were associated with higher magnitu
6                               In conclusion, heteroclitic analogs were identified in each of the six
7  much more antigenic than wild-type peptide (heteroclitic analogs).
8 s, an immune response to the cross-reactive, heteroclitic analogues of tolerized self Ags may represe
9                          Interestingly, only heteroclitic analogues, as measured in vitro by their en
10 sgenic T cells followed by immunization with heteroclitic antigen failed to terminate the state of to
11 n with certain MCC 88-103 analogues that are heteroclitic antigens as assessed on representative MCC
12 aper, the mechanism of breaking tolerance by heteroclitic antigens was investigated.
13 mined whether analogue epitopes could elicit heteroclitic antitumor T-cell responses versus wild-type
14         The anti-PC Abs in V1(-/-) mice were heteroclitic, binding to nitrophenyl-PC better than to P
15 ing of target cells pulsed not only with the heteroclitic but also with the native peptide.
16 ase the half-life and surface density of the heteroclitic complex, but precisely how this enhanced T
17 e of class I:peptide:TCR structure to design heteroclitic CTL vaccines that exploit the expression of
18                         We also identified a heteroclitic epitope (RCVIFANI) that elicited a T cell r
19 d peptide/MHC complex display contributes to heteroclitic epitope efficacy and describe parameters fo
20                       Furthermore, the ideal heteroclitic epitope will elicit T cell responses that c
21  DNA immunization, the presence of an hgp100 heteroclitic epitope with a higher affinity for MHC crea
22          The strong CTL immunity elicited by heteroclitic epitopes suggest that they could be of sign
23                   These results suggest that heteroclitic Ig-derived peptides can enhance immunogenic
24 sults establish the in vivo applicability of heteroclitic immunization against tumors, including immu
25 ntigen was expressed as a tumor antigen, and heteroclitic immunization with peptides and DNA was used
26                    This finding confirms the heteroclitic nature of at least one of the variant pepti
27 d not only enhanced cytotoxicity against the heteroclitic peptide but also increased killing of antig
28 peptide tetramers after stimulation with the heteroclitic peptide compared with the native peptide.
29                   CTLs generated against the heteroclitic peptide had not only enhanced cytotoxicity
30 ccination with dendritic cells pulsed with a heteroclitic peptide provided FVB/N and neu-N mice with
31 -specific T cells elicited in patients after heteroclitic peptide vaccination.
32 essed by melanoma cells was used to design a heteroclitic peptide vaccine that successfully induced t
33                                              Heteroclitic peptides are used to enhance the immunogeni
34 TLs specific for BAX-delta epitopes or their heteroclitic peptides could be expanded from normal dono
35                       CTLs generated against heteroclitic peptides could kill patients' tumor cells,
36 s found that in 18 Ig-derived peptides, that heteroclitic peptides from the Ig gene with improved bin
37             In contrast, strong agonists and heteroclitic peptides induced early phase T cell activat
38 at the MHC-binding residues of the peptides (heteroclitic peptides).
39                             The use of such "heteroclitic" peptides allowed generation of cytotoxic T
40     These T cells showed a crossreactive and heteroclitic (stronger) response to deamidated gluten pe
41                                         This heteroclitic T cell response associated with changes in
42 killing of cells prepulsed with a synthetic, heteroclitic variant of MART1(27-35).

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。